AnalystBook Research · Company Intelligence

ImageneBio, Inc.

IMANasdaq

Built from ImageneBio, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

ImageneBio, Inc.: Revenue declined 77.1% to $800K from $3.5M. Net loss widened to $45.35M from $36.57M. Free cash flow outflow widened to $47.84M from $21.32M. Operating margin contracted 499924 bps to -6056.38%. ImageneBio, Inc.'s annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context.

The read at a glance✓ Audited against SEC data
  • Growth — Revenue declined 77.1% to $800K from $3.5MWatch
  • Profitability — Net loss widened to $45.35M from $36.57MWatch
  • Cash flow — Free cash flow outflow widened to $47.84M from $21.32MWatch
  • Margins — Operating margin contracted 499924 bps to -6056.38%Watch
  • Accounting — Controls ineffective; material weaknessWatch
  • Insiders — 1 purchase and 0 salesOK

Business

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 96 ITEM 6. [Reserved] 96 ITEM 7.

Leadership changes

From ImageneBio, Inc.'s own filings, the day they're filed.

  • Erin Butler · President · departureeff. 2026-03-20
  • Steven Hui Wang · member · departureeff. 2026-02-12
  • Yufang Lu · Chief Medical Officer · departureeff. 2025-12-31

Latest filings

  • 8-K · Company announcement2026-08-05
  • 10-Q · Quarterly report2026-08-05
  • 8-K · Company announcement2026-07-23
  • 8-K · Company announcement2026-06-26
  • 8-K · Company announcement2026-06-17
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about ImageneBio, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full IMA record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.